Spectranetics P017517-00 GlideLight Laser Sheath Instruction Manual

Instructions for Use

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician with appropriate training.

Description

GlideLight Laser Sheath is similar in construction to the SLS II Laser Sheath family of products with the addition of 80Hz maximum repetition rate capability. The 80Hz maximum repetition rate capability is designed to improve ease of use by reducing advancement force through tissue during laser photoablation. After calibration, GlideLight Laser Sheath defaults to an 80Hz repetition rate.
The Laser Sheath Kit includes a 12F, 14F, or 16F Laser Sheath, two Outer Sheaths, and a Fish Tape. The Laser Sheath is an intra-operative device used to free a chronically implanted pacing or defibrillator lead.
The Laser Sheath consists of optical fibers arranged in a circle, sandwiched between inner and outer polymer tubing. The fibers terminate at the distal end within a polished tip and at the proximal end within the coupler that mates with the excimer laser system. At the distal tip, the fibers are protected by inner and outer stainless steel bands, which form a radiopaque marker. The inner lumen of the device is designed to allow a pacing lead to passing through it, as the device slides over the lead towards the tip of the lead in the heart.
The Laser Sheath is designed for use only with the Spectranetics CVX-300 Excimer Laser System. The multifiber Laser Sheaths transmit ultraviolet energy from the Spectranetics CVX-300 laser to the tissue at the distal tip of the device. When the laser fires, a small amount of the tissue is ablated, thereby freeing the lead from overgrowth in a controllable fashion.
The Laser Sheath is used in conjunction with conventional lead extraction tools (e.g., locking stylets, outer sheaths).
The Spectranetics Outer Sheath is a 43 cm long single-lumen tubing designed to fit over the Laser Sheath. The tube is cut at a 45-degree angle on one end and the edges are beveled on both ends. The Outer Sheath is used during the extraction procedure as an introducer and to support and align the Laser Sheath. It is used as a conduit to remove the Laser Sheath with the extracted lead and can be used as a conduit to implant a new lead.
The Fish Tape is an accessory to assist in the loading of the Laser Sheath over an implanted lead. The Fish Tape is a stainless steel mandrel with a wire loop handle on one end and a closed wire hook on the other end.

Indications for Use

The Laser Sheath is intended for use as an adjunct to conventional lead extraction tools in patients suitable for transvenous removal of chronically implanted pacing or defibrillator leads constructed with silicone or polyurethane outer insulation.

Contraindications

Use of the Laser Sheath is contraindicated: · When emergency thoracotomy with cardiopulmonary bypass can not be performed immediately in the event of a life-threatening complication;

• When fluoroscopy is not available;
• In patients in whom superior venous approach cannot be used;
• When the proximal end of the pacing lead is not accessible to the operator;
• When the lead will not fit into the inner lumen of the Laser Sheath.

Warnings

Do not attempt to operate the Laser Sheath without the availability of conventional lead extraction tools.
Lead removal devices should be used only at institutions with emergency cardiac surgical capabilities and complication prevention and management protocols in place and routinely practiced. The recommendations for lead management of the Heart Rhythm Society1 (HRS) and European Heart Rhythm Association2 (EHRA) are strongly suggested.
The majority of adverse events observed in post-market surveillance have involved the proximal coil or dual coil ICD leads in the SVC. Therefore, particular care must be taken when removing these leads. In addition, as with all extractions, a risk-to-benefit assessment for the removal of these leads should be considered for each patient.
The Laser Sheath should be used only by physicians who are experienced in pacing lead removal techniques using telescoping dilator sheaths.
The CVX-300 Excimer Laser System should be used only by physicians who have received adequate training (See Section 12.3).
Protective glasses are required when the laser is in use. Avoid eye or skin exposure to direct or scattered radiation. Refer to exposure label on the CVX-300 Excimer Laser System.
Do not insert more than one Laser Sheath or Outer Sheath into a vein at a time. Severe vessel damage, including venous wall laceration requiring surgical repair, may occur.
Do not place the outer sheath tip at the SVC-atrial junction as it may damage this delicate area during subsequent procedures, e.g., moving the outer sheath, implanting a new lead.
Maintain appropriate traction on the lead being extracted during advancement of the Laser Sheath or outer sheath.
When marked calcification that moves with the lead to be extracted is seen on fluoroscopy, particularly in the atrium, the availability of immediate surgical assistance is paramount if a problem presents itself as a result of the extraction procedure. Also, an indication for thoracotomy removal of the lead(s) should be considered.
Do not advance the Laser Sheath any closer than 1 cm from the lead tip. Do not lase at the myocardium to free the lead tip.

Precautions

Thoroughly review the package insert for conventional lead extraction tools before attempting to use the Laser Sheath.
For single use only. Do not resterilize and/or reuse
DO NOT resterilize or reuse this device, as these actions can compromise device performance or increase the risk of cross-contamination due to inappropriate reprocessing. Reuse of this single-use device could lead to serious patient injury or death and voids manufacturer warranties.

Do not use the Laser Sheath:

• If the tamper-evident seal is broken;
• If the Laser Sheath has been damaged. 1 Wilkoff B.L., et al. Transvenous
  Lead Extraction: Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient Management. Heart Rhythm. July 2009. 2 Deharo J.C., et al. Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper. Europace (2012) 14, 124-134.

When the Laser Sheath is in the body, it should be manipulated only under fluoroscopic observation with radiographic equipment that provides high quality images.
Approximately half the forward advancement force is needed to progress with 80 Hz operation at the same rate as with 40 Hz operation. The recommended advancement rate is 1 mm per second.

Adverse Events

All devices used to evaluate lead removal in these clinical studies were the SLS, which used a maximum repetition rate of 40Hz. No clinical data has been collected using the GlideLight Laser Sheath, which operates using a maximum repetition rate of 80Hz. Therefore, complication rates presented in Tables 1 and 2 below are reflective of the complication rates observed with the use of the 40Hz Laser Sheath model (SLS).
6.1 Observed Adverse Events
Adverse events observed for the 12F, 14F, and 16FLaser Sheaths in clinical studies are reported in Tables 1 and 2 below. Table 1 reports adverse event information from the 301-patient randomized study of lead removal with the 12F Device (LASER) and conventional lead extraction tools (Non-LASER). Table 2 reports adverse event information from a 180-patient registry study of lead removal with the 14F And 16F devices. Adverse event rates for the 12F device from the randomized study is included in Table 2 for comparison to the larger devices.
Table 1. Acute Complications and Complications at 1-month
All Randomized Patients (n=301)
Laser Device: 12F

| LASER (N=153)| Non-LASER (N=148)| TOTAL (N=301)
---|---|---|---
Complications – Acute| n| %| n| %| n| %
Perioperative Death| 1| 0.7%| 0| 0| 1| 0.3%
Hemopericardium tamponade| 2| 1.3%| 0| 0| 2| 0.7%
Hemothorax| 1| 0.7%| 0| 0| 1| 0.3%
Complications – One Month| LASER (N=145)| Non-LASER (N=140)| TOTAL (N=285)
Death| 2| 1.4%| 1| 0.7%| 3| 1.1%
Complications – any| 4| 2.8%| 3| 2.1%| 7| 2.5%
Pain at cut-down site| 1| 0.7%| 0| 0.0%| 1| 0.4%
Arm swelling| 1| 0.7%| 1| 0.7%| 2| 0.7%
Infection| 1| 0.7%| 1| 0.7%| 2| 0.7%
SVC thrombosis| 0| 0.0%| 1| 0.7%| 1| 0.4%
Tricuspid regurgitation| 1| 0.7%| 0| 0.0%| 1| 0.4%

Table 2. Acute Complications and Complications at 1-month
Laser-Treated Patients: 14F, 16F, and 12F Devices

| 14F (N=97)| 16F (N=83)| 12F (N=153)| TOTAL (N=333)
---|---|---|---|---
Complications – Acute| n| %| n| %| n| %| n| %
Perioperative Death| 2| 2.1%| 1| 1.2%| 1| 0.7%| 4| 1.2%
Hemopericardium tamponade| 3| 3.1%| 3| 3.6%| 2| 1.3%| 8| 2.4%
Hemothorax| 0| 0%| 0| 0%| 1| 0.7%| 1| 0.3%
Perforation| 0| 0%| 1| 1.2%| 0| 0%| 1| 0.3%
Other| 1| 1.0%| 1| 1.2%| 0| 0%| 2| 0.6%
| 14F (N=78)| 16F (N=72)| 12F (N=145)| TOTAL (N=295)
Complications – One Month| n| %| n| %| n| %| n| %
Death| 1| 1.3%| 0| 0%| 2| 1.4%| 3| 1.0%
Complications – any| 2| 2.6%| 0| 0%| 4| 2.8%| 6| 2.0%
Pain at cut-down site| 0| 0%| 0| 0%| 1| 0.7%| 1| 0.3%
Arm swelling| 1| 1.3%| 0| 0%| 1| 0.7%| 2| 0.7%
Infection| 0| 0%| 0| 0%| 1| 0.7%| 1| 0.3%
Tricuspid regurgitation| 0| 0%| 0| 0%| 1| 0.7%| 1| 0.3%
Phlebitis| 1| 1.3%| 0| 0%| 0| 0%| 1| 0.3%

6.2 Potential Adverse Events
The following adverse events or conditions may also occur during lead extraction with the Laser Sheath, but were not observed during the clinical study (listed in alphabetical order):

• bacteremia
• low cardiac output
• migration of lead fragments
• migration of vegetation
• myocardial avulsion / perforation
• premature ventricular contractions
• pulmonary embolism
• stroke
• venous avulsion / perforation
• ventricular tachycardia

Clinical Study

All devices used to evaluate lead removal in these clinical studies were SLS, which used a maximum repetition rate of 40Hz. No clinical data have been collected using the GlideLight Laser Sheath, which operates using a maximum repetition rate of 80Hz. Therefore, the effectiveness and safety data presented in Tables 3, 4, and 5 below are reflective of the data obtained with the use of the 40Hz Laser Sheath model (SLS).

7.1 Randomized Trial
Purpose: The use of standard tools (NonLASER) only (locking stylets, polymer, and stainless steel sheaths, grips, snares, etc.) to explant chronically implanted pacing and defibrillator lead as compared to standard tools plus the 12F Laser Sheath (LASER). The primary effectiveness measure was the proportion of complete extractions (per lead basis). The primary safety measure was complication rate (per-patient basis).
Methods: Patients with mandatory or necessary indications for lead removal and with the targeted lead implanted at least one year prior were randomized into the LASER or NonLASER groups in nine US centers between 11/95 and 10/96. The primary endpoint was reached if the lead was completely explanted. If the lead fractured, leaving the tip and possibly a portion of the conductor in the patient, the removal was judged a “partial success.” The extraction was judged a procedural failure if any of five events occurred: change to femoral or transatrial approach, failure to gain venous entry, failure of sheaths to pass a binding site, lead breakage, or onset of a complication. A crossover from NonLASER tools to laser tools was allowed after failure. Crossover patients were analyzed separately. Procedure time, defined as wall-clock time from the moment sheaths were applied until an endpoint was reached, was also recorded.

Description of Patients: 365 patients were enrolled. Five patients were found to meet exclusion criteria after enrollment and were disqualified from the study before any treatment was administered; thus 360 patients were treated. 59 nonrandomized patients were enrolled for investigator training. The remaining 301 patients (with 465 leads) presented with mandatory or necessary indications for lead removal. The mean patient age was 65 years (range 4 to 94) with 36% females and a mean implant duration of 67 months (range 1 to 286). Patient characteristics were similar between the two randomized groups.

Results:
Table 3. Principal Effectiveness and Safety Results.
Laser vs. Non-Laser

Effectiveness: Leads

| Laser| Non-Laser| Difference In
---|---|---|---
~| N| Complete| Partial| Failure| N| Complete| Partial| Failure|

Failure [95% CI]

Of First Treatment| 244| 230 (94.3%)| 6 (2.4%)| 8 (3.3%)| 221| 142 (64.2%)| 4 (1.9%)| 75 (33.9%)| -29.8% [-23%,-36%]
Of Crossover Treatment| ~| ~| ~| ~| 72| 63 (87.5%)| 3 (4.2%)| 6 (8.3%)| ~
Of Final Treatment| 244| 230 (94.3%)| 6 (2.4%)| 8 (3.3%)| 221| 205 (92.8%)| 7 (3.1%)| 9 (4.1%)| -0.8% [-2.8%,4.2%]
Total Proc. Time| 244| 11.2| ±13.9 min| ~| 221| 14.2| ±21.6 min| ~| -3.05 [-3.12,-2.97]
Safety Results: Patients| Nª| Laser| N b| Non- Laser| Difference
Acute Complications| 218| 3 (1.4%) [0.3%, 4.0%]| 83| 0 (0.0%) [0.0%, 4.4%]| 1.4% [-0.2%, 2.9%]
Complications 1mo.| 218| 6 (2.8%) [1.0%, 5.9%]| 83| 1 (1.2%) [0.0%, 6.5%]| 1.5% [-1.7%, 4.7%]
Death, perioperative| 218| 1 (0.5%) [0.0%, 2.5%]| 83| 0 (0.0%) [0.0%, 4.4%]| 0.5% [-0.3%, 1.1%]
Death 1mo.| 218| 2 (0.9%) [0.1%, 3.3%]| 83| 1 (1.2%) [0.0%, 6.5%]| -0.3% [-3.0%, 2.4%]

Total Proc. Time (mean ± s.d.) = procedure time for FirstTreatment + time for Crossover Treatment(ifany) CI = Confidence intervals via binomial approximation (Effectiveness) or exact binomial method (Safety)

• = difference statistically significant (p < 0.001) by Chi-Square with continuity correction, or t-test
  a includes patients randomized to LASER plus Crossover patients
  b includes patients randomized to NonLASER less Crossover patients
  Difference = LASER-NonLASER; SEM = sqrt(p1q1/n1 + p2q2/n2); 95% CI = Diff ± 1.96*SEM

7.2 Registry Trial
Purpose: Registry usage of the 14F and 16F Laser Sheaths to explant chronically implanted pacing and defibrillator leads was compared to the outcomes of the 12F Laser Sheath randomized study.
The primary effectiveness measure was the proportion of complete extractions (per lead). The primary safety measure was complication rate (per patient).

Methods: Patients with mandatory or necessary indications for lead removal and with the targeted lead implanted at least one year prior were treated at 32 US centers between 6/97 and 2/98. The primary endpoint was reached if the lead was completely explanted. If the lead fractured, leaving the tip and possibly a portion of the conductor in the patient, the removal was judged a “partial success.”
The extraction was judged a procedural failure if any of four events occurred: change to femoral or transatrial approach, failure to gain venous entry, failure of sheaths to pass a binding site or onset of a complication. Procedure time, defined as wall-clock time from the moment sheaths were applied until an endpoint was reached, was also recorded.

Description of Patients: 180 registry patients were enrolled and treated (97 for 14F, 83 for 16F). The mean patient age for the 14F group was 69 years (range 13 to 86) with 57% males; this did not differ significantly from the 12F randomized group. The implant duration of leads treated with the 14F device was significantly longer than the control group (85 ± 50 months vs. 65 ± 42 months). For the 16F group mean patient age was 62 years (range 9 to 85) with 77% males; these values were also not significantly different from the control group. The implant duration of leads treated with the 16F device was 68 ± 60 months and was not significantly different from the control group.

Results:
Table 4. Principal Effectiveness and Safety Results.
14F vs. 12F

14F

|
---|---
Effectiveness: Leads| N| Complete| Partial|

Failure

Outcome| 164| 142 (88.6%)| 12 (7.3%)| 10 (6.1%)
Safety: Patients| N| Observed| Confidence Interval
Acute Complications| 97| 4 (4.1%)| [0.2%, 8.1%]
Complications, 1mo.| 78| 2 (2.6%)| [0.0%, 6.1%]
Death, perioperative| 97| 2 (2.1%)| [0.0%, 4.9%]
Death, 1 mo.| 78| 1 (1.3%)| [0.0%, 3.8%]
12F| Difference in Failure
Effectiveness: Leads| N| Complete| Partial| Failure| [95% CI]
Outcome| 244| 230 (94.3%)| 6 (2.5%)| 8 (3.3%)| 2.8% [-1.5%, 7.1%]
Safety: Patients| N| Observed| Confidence Internal| Difference [95% CI]
Acute Complications| 218| 3 (1.4%)| [0.3%, 4.0%]| 2.7% [-2.2%, 7.7%]
Complications, 1 mo.| 218| 6 (2.8%)| [1.0%, 5.9%]| 1.6% [-2.1%5.3%]
Death, perioperative| 218| 1 (0.5%)| [0.0%, 2.5%]| 1.6% [-2.1%, 5.3%]
Death, 1 mo.| 218| 2 (0.9%)| [0.1%, 3.3%]| 0.4% [-3.3%, 4.0%]

Table 5. Principal Effectiveness and Safety Results.
16F vs. 12F

16F|
---|---
Effectiveness: Leads| N| Complete| Partial| Failure
Outcome| 97| 86 (88.7%)| 2 (2.1%)| 9 (9.3%)
Safety: Patients| N| Observed| Confidence Interval
Acute Complications| 83| 5 (6.0%)| [0.9%, 11.1%]
Complications, 1mo.| 72| 0 (0.0%)| [0.0%, 0.0%]
Death, perioperative| 83| 1 (1.2%)| [0.0%, 3.6%]
Death, 1 mo.| 72| 0 (0.0%)| [0.0%, 0.0%]
12F| Difference in Failure
Effectiveness: Leads| N| Complete| Partial| Failure| [95% CI]
Outcome| 244| 230 (94.3%)| 6 (2.5%)| 8 (3.3%)| 6.0% [-2.0%, 12.2%]
Safety: Patients| N| Observed| Confidence Internal| Difference [95% CI]
Acute Complications| 218| 3 (1.4%)| [0.3%, 4.0%]| 4.6% [-1.5%, 10.8%]
Complications, 1 mo.| 218| 6 (2.8%)| [1.0%, 5.9%]| -2.8% [-5.8%, 0.3%]
Death, perioperative| 218| 1 (0.5%)| [0.0%, 2.5%]| 0.7% [-2.6%, 4.1%]
Death, 1 mo.| 218| 2 (0.9%)| [0.1%, 3.3%]| -0.9% [-3.1%, 1.3%]

Individualization of Treatment

Weigh the relative risks and benefits of the intravascular catheter/lead removal procedures in cases when:

• Dual coil ICD leads are being removed;
• The lead to be removed has a sharp bend or evidence of fracture;
• The lead shows evidence of insulation disintegration raising the concern of pulmonary embolism;
• Vegetations are attached directly to the lead body.

When an outer sheath, used in conjunction with the Laser Sheath during the lead extraction procedure, is left in place once the Laser Sheath and lead are removed from the patient, the outer sheath may then be used as a conduit for a guidewire to facilitate the implantation of a new lead.
The outer sheath tip should be either (a) fully into the atrium, or (b) retracted into the brachiocephalic vein. Placing the outer sheath tip at the SVC-atrial junction risks damage to this delicate area during subsequent procedures, such as moving the outer sheath or implanting a new lead, and is thus not recommended.
It is vital that appropriate traction be maintained on the lead being extracted both during laser-assisted and standard extraction attempts. If appropriate levels of traction cannot be maintained on the lead in order to offset the counter-pressures that distort the lead body, then changing to an alternative extraction methodology such as the femoral approach would be indicated.
When marked calcification that moves with the lead to be extracted is seen on fluoroscopy, particularly in the atrium, the availability of immediate surgical assistance is paramount if a problem presents itself because of the extraction procedure. Also, an indication for thoracotomy removal of the lead(s) should be considered.
The safety and effectiveness of the Laser Sheath has not been established for the following:

• Patients with a recent history of pulmonary embolus
• Laser Sheath advancement into the coronary sinus

Operator’s Manual

Energy Parameters
The devices described in this document can be operated within the following energy ranges on the CVX-300:

Default energy settings following calibration are 60 Fluence, 80 Hz
Version 3.X18 or higher software for the CVX-300 is necessary to operate this device. CVX-300s with V3.7XX software will limit the repetition rate to 40Hz.
The CVX-300 will allow these devices to operate for a period of 10 seconds, after which a 5-second wait will be imposed before lasing can resume.

How Supplied

10.1 Sterilization
For single use only. Do not re-sterilize and/or reuse.
This device has been sterilized using Ethylene Oxide and is supplied sterile. Sterility is guaranteed only if the package is unopened and undamaged.
10.2 Transportation and Storage
Keep dry. Store in a cool dry place. Protect from direct sunlight and high temperature (greater than 60°C or 140°F).
Repetition Rate (Hz) 25-80 25-80 25-80
10.3 Inspection Prior to Use
Before use, visually inspect the sterile package to ensure that seals have not been broken. All equipment to be used for the procedure, including the Laser Sheath, should be examined carefully for defects.
Examine the Laser Sheath for bends, kinks or other damage. Do not use it if it is damaged or unintentionally opened.

Compatibility

Compatibility of Laser Sheath and Pacemaker/ICD Lead The table below shows the dimensional compatibility between the Laser Sheath, the Pacemaker/ICD Lead to be removed, and the Outer Sheath. It is vital that the physician determines the maximum outside diameter (OD) of the lead before extraction with the Laser Sheath is attempted. This information should be obtained from the lead manufacturer.

ID = Inside Diameter OD
= Outside Diameter| 12F Laser Sheath| 14F Laser Sheath| 16F Laser Sheath
---|---|---|---
Model #| 500-301| 500-302| 500-303
Minimum Tip ID, in. / Fr /mm| 0.109 / 8.3 / 2.77| 0.134 / 10.2 / 3.40| 0.164 / 12.5 / 4.17
Maximum Tip OD, in. / Fr / mm| 0.164 / 12.5 / 4.17| 0.192 / 14.7 / 4.88| 0.225 / 17.2 / 5.72
Lead: Maximum OD, Fr / mm| 7.5 / 2.50| 9.5 / 3.17| 11.5 / 3.83
Outer Sheath: Minimum ID, Fr/mm| 13 / 4.33| 15.5 / 5.17| 18.2 / 6.07

Directions for Use

12.1 Procedure Set Up
Laser Sheath preparations:

1. Using the sterile technique, open the sterile package. Remove the packaging wedges from the tray and gently lift the device from the tray while supporting the proximal coupler.
2. Connect the proximal end of the device to the connector of the theCVX-300.
3. Calibrate the Laser Sheath following the instructions in the “Operational Modes” section of the CVX-300 Operator’s Manual (7030-0035 or 7030-0068).

Patient preparations:

1. Obtain thorough patient history, including patient blood type. Appropriate blood products should be readily available.
2. Ascertain the manufacturer, model number, and implant date of the catheter/lead to be removed. Perform radiographic/echocardiographic evaluation of catheter/lead condition, type, and position.
3. Use a procedure room that has high-quality fluoroscopy, pacing equipment, defibrillator, thoracotomy, and pericardiocentesis trays.
4. Prep and drape the patient’s chest for possible thoracotomy; prep and drape the patient’s groin for a possible femoral approach extraction procedure.
5. Establish backup pacing as needed.
6. Have available additional Laser Sheaths, Outer Sheaths, locking stylets, stylets to unscrew active fixation leads, snares (femoral workstation), and any other accessory equipment deemed necessary.

12.2 Clinical Technique

1. Patients prepared for lead extractions are prepared for multiple approaches, including an emergency cardiac surgical procedure. Preparations may include: general endotracheal anesthesia or conscious sedation, shave and preparation of both the chest and groin areas, ECG monitoring, insertion of an arterial line and a Foley catheter, presence of instruments for pacing and defibrillation, an electrosurgical unit, and a sternal saw for emergencies.
2. A temporary pacing lead is inserted in all patients needing a pacemaker. An exception is made for patients with an implanted permanent pacemaker whose leads are not to be extracted.
3. Fluoroscopy will be used to monitor all transvenous maneuvers.
4. Expose the proximal end of the lead and sever any suture holding the anchoring sleeve suture. Debride overgrowth from the lead as required to expose the venous entry site. Sever the lead connector and remove the anchoring sleeve
5. For active fixation leads, unscrew the lead helix.
6. Sever the lead terminal pin connector and remove the anchoring sleeve.
7. Insert and lock a locking stylet or Lead Locking Device into the lead as distal as possible and deploy the locking mechanism. Secure a length of suture material approximately 60 cm long to the proximal end of the lead insulation and high voltage cables to provide additional traction.
8. Fill a sterile syringe with 10 ccs of saline solution. Inject the saline into the inner lumen of the Laser Sheath. Using another 10 cc of saline, wet the outer jacket of the Laser Sheath.
9. When using an outer sheath, wet the inner lumen and place it over the Laser Sheath.
10. Using a “Fish Tape” device, thread the handle of the traction device through the inner lumen of the Laser Sheath. Remove the “Fish Tape” after the traction device handle emerges from the proximal end of the Laser Sheath. Thread the proximal end of the lead into the inner lumen of the Laser Sheath.
11. Extraction technique:
    a. Advance the Laser Sheath over the lead until an obstruction is met. When using an outer sheath, use an “inchworm” technique to alternately advance the outer sheath and the Laser Sheath over the lead.

PRECAUTION: Approximately half the forward advancement force is needed to progress with 80 Hz operation at the same rate as with 40 Hz operation. The recommended advancement rate is 1 mm per second.
PRECAUTION: When advancing a Laser Sheath or outer sheath around a bend, keep the point of the sheath’s beveled tip oriented toward the inside of the bend.
PRECAUTION: As in all extraction procedures using a laser sheath, but particularly when removing dual-coil ICD leads, maintain sturdy traction and a stable “rail” position with the lead while keeping the coaxial alignment of the laser sheath and the bevel on the inside curvature of the SVC.
PRECAUTION: Before entering the SVC, stop to ensure sturdy traction and a stable “rail” are maintained.
b. Use the following guidelines to determine if a tissue obstruction is met:

• The Laser Sheath will not advance into the vein.
• The Laser Sheath bows outward slightly when longitudinal pressure is applied.
• Fluoroscopy shows that the sheath tip does not advance relative to the lead body.
• Fluoroscopy shows that the Laser Sheath tip is not caught on a lead electrode, a lead bend, or another lead.

c. When an obstruction is met and the Laser Sheath cannot be advanced:

• Use orthogonal fluoroscopic views to ensure that the tip of the Laser Sheath is aligned and coaxial with the longitudinal axis of the lead.
• Retract the outer sheath so that its distal end does not overlap the tip of the Laser Sheath. Press the Laser Sheath gently into the obstructing tissue.
• Place the laser in READY mode. Depress the footswitch, activating the laser. While the laser is firing, use gentle pressure on the Laser Sheath to advance the device approximately 1 mm per second while applying equal and opposite traction to the traction device. If the Laser Sheath breaks through the obstruction during lasing, release the footswitch.

PRECAUTION: Advancing the Laser Sheath through moderately calcified tissue may require more pulses of laser energy than through fibrous scar overgrowth.
PRECAUTION: Stop if not able to advance the laser sheath. Be prepared to upsize to a larger laser sheath, move to another lead, try a femoral approach or consider an open procedure. Also, consider abandoning the procedure by leaving the lead in place and referring to a more experienced center.

• Advance the outer sheath to the new position of the Laser Sheath.

d. If the traction device unlocks its grip on the lead, it is necessary to remove the Laser Sheath and outer sheath and apply a new traction device, before proceeding again with the Laser Sheath.
e. Advance the outer sheath and Laser Sheath to the desired location on the lead, as described in 11 (a-c) above. Do not advance the Laser Sheath any closer than 1 cm from the lead tip. Do not lase at the myocardium to free the lead tip.
WARNING: Do not advance the Laser Sheath any closer than 1 cm from the lead tip. Do not lase at the myocardium to free the lead tip.
f. If necessary, use counter traction, using the outer sheath and the traction device, to free the lead tip from the heart wall.
12. Withdrawal of the Laser Sheath and outer sheath can be accomplished at any time during the procedure. If the lead is free, it should be drawn into the Laser Sheath before the lead, the Laser Sheath,
and the outer sheath is removed from the body.
13. To retain venous access for re-implant, keep the outer sheath in place for guidewire insertion when removing lead and Laser Sheath. Remove the outer sheath from the body after the guidewire is inserted.
PRECAUTION: If the Laser Sheath is removed from the body for any reason, thoroughly clean the device shaft, inner lumen, and tip with saline to remove particles and prevent blood from sticking.
PRECAUTION: If the Laser Sheath becomes kinked or damaged during use as evidenced by fluoroscopy, it is recommended to discontinue the use of the device. Weigh the relative risks and benefits of device removal versus continued use.
12.3 Physician Training
Physician training in the use of the Laser Sheath and CVX-300 Excimer Laser System should include:

• Classroom training in laser safety and physics;
• A didactic presentation of laser operation followed by a demonstration of the CVX-300 Excimer Laser System;
• Hands-on training in the use of the CVX-300 Excimer Laser System in lead removal;
• Observation of the removal of at least two leads with the Laser Sheath performed by an experienced Laser Sheath user;
• Removal of at least two leads in the presence of a second physician experienced in lead removal techniques and a fully trained Spectranetics representative.
• HRS1 and EHRA2 recommendations for complication management.

Manufacturer’s Limited Warranty

Manufacturer warrants that the GlideLight Laser Sheath is free from defects in material and workmanship when used by the stated “Use By” date. The manufacturer’s liability under this warranty is limited to replacement or refund of the purchase price of any defective unit of the GlideLight Laser Sheath. The manufacturer will not be liable for any incidental, special, or consequential damages resulting from the use of the GlideLight Laser Sheath. Damage to the GlideLight Laser Sheath caused by misuse, alteration, improper storage or handling, or any other failure to follow these Instructions for Use will void this limited warranty. THIS LIMITED WARRANTY IS EXPRESSLY IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THE IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. No person or entity, including any authorized representative or reseller of the Manufacturer, has the authority to extend or expand this limited warranty, and any purported attempt to do so will not be enforceable against the Manufacturer. This limited warranty covers only the GlideLight Laser Sheath. Information on the Manufacturer’s warranty relating to the CVX-300 Excimer Laser System can be found in the documentation relating to that system.

Non-Standard Symbols

(mJ) at 60 Fluent
****Size| ****Laser Sheath| ****Maximum Repetition Rate
Outer Sheaths| Fish Tape| Quantity QTY**

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.

Applicable Standards

The standards identified in Table 15.1 were applied to the development of the device.
Table 15.1: Standards applied to the development of the GlideLight

Standard/Norm and Date

|

Title

---|---
Biocompatibility:
ISO 10993-1| Biological evaluation of medical devices – Part 1: Evaluation of testing
Clinical Study:
EN ISO 14155| Clinical Investigation of medical devices for human subjects
Design:
ANSI Z136.1| Safe Use of Lasers
EN ISO 10555-1| Sterile, single-use intravascular catheters – Part 1: General requirements
US 21 CFR 820| Quality System Regulation
Environmental:
ISO 14644-1| Cleanrooms and associated controlled environments – Part 1: Classification of air cleanli- ness.
ISO 14644-2| Cleanrooms and associated controlled environments – Part 2: Specification for testing and monitoring to prove continued compliance with ISO 14644-1.
Labeling:
EN 556-1| Sterilization of Medical Devices. Requirements for medical devices to be designated “STERILE”. Requirements for terminally sterilized medical devices.
EN 980| Graphical symbols for use in the labeling of Medical Devices.
EN 1041| Information supplied by the manufacturer with medical devices
ISO 15223| Medical devices Symbols to be used with medical device labels, labeling, and information to be supplied
Packaging:
EN ISO 11607-1| Packaging for terminally sterilized medical devices – Part 1: Requirements for materials, sterile barrier systems, and packaging systems
EN ISO 11607-2| Packaging for terminally sterilized medical devices – Part 2: Validation requirements for forming, sealing, and assembly processes
ISO 780| Packaging – Pictorial marking for the handling of goods
Quality:
EN ISO 13485| Medical devices — Quality management systems
Risk Management:
EN ISO 14971| Medical Devices – Application of risk management to medical devices
EN 62366| Medical Devices – Application of usability engineering to medical devices
Sterilization:
EN ISO 11135| Sterilization of health care products – Ethylene oxide – Part 1: Requirements for development, validation, and routine control of a sterilization process for medical devices

Disposal

Use and disposal must be in accordance with generally accepted medical practice and applicable local, state, and federal laws and regulations.
Products may pose a potential biohazard after use.
If the packaging is damaged and/or the expiration date expires, the product is to be disposed of in accordance with the rules for the treatment of medical waste class A according to SanPiN 2.1.7.2790-10.
The used product is disposed of in accordance with the rules for the management of medical waste class B according to SanPiN 2.1.7.2790-10.

www.spectranetics.com
Spectranetics Corporation
9965 Federal Drive, Colorado Springs, CO 80921
USA Tel: 1-800-231-0978
Fax: 1-719-447-2022
Authorized Russian Representative: 13, Sergey Makeev Str., Moscow, 123022,
Russia PHILIPS Limited Liability Company cmo-rca@philips.com
Contacts of the Attorney:
(Tel: (495) 937 93 00
Fax: (495) 937-93-07)
2021 Spectranetics Corporation

References

• Spectranetics | Philips

Read User Manual Online (PDF format)

Download This Manual (PDF format)

Download this manual  >>